Webcast Main Sessions and Satellite Symposia ISAL XVI
Main Session I: Epigenetic Changes in Acute Leukemias
Sunday, February 19, 2017
Main Session II: Clonal Evolution and Leukemic Stem Cells
Sunday, February 19, 2017
- J. S. Welch, St. Louis: Origin of Mutations in Acute Myeloid Leukemia
- M. J. Walter, St. Louis: Clonal Architecture of Secondary AML
Welcome Address
Monday, February 20, 2017
Main Session III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis
Monday, February 20, 2017
- R. Bejar, La Jolla: Clonal Hematopoiesis, ICUS and MDS: Diagnostic Challenges and Clinical Relevance
Thomas-Büchner Lecture
Monday, February 20, 2017
Main Session IV: Novel Approaches and Targeted Therapies in AML
Monday, February 20, 2017
- E. H. Estey, Seattle: Endpoints for New Drug Approvals in AML
- M. Konopleva, Houston: Targeted Agents in AML (ABT199)
- R. M. Stone, Boston: FLT3-Inhibition in FLT3 Mutated AML
- M. J. Levis, Baltimore: A Perspective on FLT3 Inhibitor Trials Results
- M. S. Tallman, New York: Targeting IDH Mutations in AML
- G. J. Roboz, New York: Bromodomain Inhibition in AML
Main Session VI: Risk Adapted Therapy of AML
Tuesday, February 21, 2017
- N. G. Russell, Nottingham: Risk Adapted Therapy of AMNL in MRC/NCRI Trials
- R. E. Champlin, Houston: Who should receive a Transplant in CR1?
Main Session VII: Biology and Treatment of APL
Tuesday, February 21, 2017
- E. Lengfelder, Mannheim: The AML-CG Trials in APL
- F. Lo Coco, Rome: Chemotherapy-Free Treatment in APL
- N. G. Russell, Nottingham: The Feasibility of More Attenuated Dosage Schedules in APL
- P. Montesinos, Valencia: Therapy-Related and Secondary APL
Main Session VIII: Relevance of MRD in Acute Leukemias
Tuesday, February 21, 2017
- R. B. Walter, Seattle: Using Measurable Residual Disease (MRD) Information To Guide Transplant Practice for Acute Leukemia
- Th. Köhnke, Munich: Early Detection and Alternative Gating Strategies in Flow MRD
Main Session X: Immunotherapy for Acute Leukemias
Wednesday, February 22, 2017
- J. DiPersio, St. Louis: T-Cell Recruiting Antibodies
- H. Dolstra, Nijmegen: Checkpoint Inhibition in Acute Myeloid Leukemia
- R. Bargou, Würzburg: BITE Antibodies for the Treatment of Acute Leukemias
Main Session XI: ALL: Biology and Treatment Strategies
Wednesday, February 22, 2017
- Ch. Mullighan, Memphis: The Evolving Genomic Landscape of Acute Lymphoblastic Leukemia: Subtypes, Genes and Targets
- H. Kantarjian, Houston: Can we Cure Ph Positive ALL (without Allogeneic Stem Cell Transplant?
- M. Schrappe, Kiel: Treatment of ALL in Childhood
- W. Hiddemann, Munich: CLOSING REMARKS